source
- Novartis' Zolgensma linked to tumors as FDA probes gene therapy and orders GLP-1 eye risk warningsNovartis confirmed that nine patients who received its Zolgensma gene therapy for spinal muscular atrophy have developed tumors, prompting the FDA to open an investigation into the approved treatme…
- U.S. 'most-favored nations' policy prompts drugmakers to reconsider overseas launchesThe White House's "most-favored nations" rule, which would tie foreign drug prices to U.S. prices, is causing U.S. pharma firms to rethink launching products abroad. Companies are exploring strate…